S T A T E O F N E W Y O R K
________________________________________________________________________
9830
I N A S S E M B L Y
April 11, 2024
___________
Introduced by M. of A. PAULIN -- read once and referred to the Committee
on Higher Education
AN ACT to amend the education law, in relation to the use of topical
pharmaceutical agents
THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:
Section 1. Paragraphs (d), (e) and (f) of subdivision 1 of section
7101-a of the education law, paragraph (d) as added by chapter 517 of
the laws of 1995 and paragraphs (e) and (f) as amended by chapter 506 of
the laws of 2021, are amended to read as follows:
(d) Diagnostic pharmaceuticals. Diagnostic pharmaceuticals shall mean
those drugs which shall be limited to topical applications [to the
surface of the eye] for the purpose of diagnostic examination of the eye
[and shall be limited to:
(i) Anesthetic agents;
(ii) Mydriatics;
(iii) Cycloplegics;
(iv) Miotics;
(v) Disclosing agents and other substances used in conjunction with
these drugs as part of a diagnostic procedure] AND ADNEXA.
(e) Topical therapeutic pharmaceutical agents. Topical therapeutic
pharmaceutical agents shall mean those drugs which shall be limited to
topical application [to the surface of the eye] for therapeutic purposes
[and shall be limited to:
(i) antibiotic/antimicrobials;
(ii) decongestants/anti-allergenics;
(iii) non-steroidal anti-inflammatory agents;
(iv) steroidal anti-inflammatory agents;
(v) antiviral agents;
(vi) hyperosmotic/hypertonic agents;
(vii) cycloplegics;
(viii) artificial tears and lubricants; and
(ix) immunosuppressive agents] OF THE EYE AND ADNEXA.
EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14942-02-4
A. 9830 2
(f) Therapeutic pharmaceutical agents for treatment of glaucoma and
ocular hypertension. Therapeutic pharmaceutical agents for treatment of
glaucoma and ocular hypertension shall mean those drugs which shall be
limited to topical application [to the surface] FOR THERAPEUTIC PURPOSES
of the eye and [shall be limited to:
(i) beta blockers;
(ii) alpha agonists;
(iii) direct acting cholinergic agents;
(iv) prostaglandin analogs; and
(v) carbonic anhydrase inhibitors] ADNEXA.
§ 2. Paragraph (e) of subdivision 4 of section 7101-a of the education
law, as added by chapter 517 of the laws of 1995 and as relettered by
chapter 506 of the laws of 2021, is amended to read as follows:
(e) The provisions of paragraphs (a) and (b) of this subdivision shall
not apply to (i) graduates of an appropriate program approved by the
department who have successfully passed the examination on the use of
diagnostic and therapeutic [drugs] AGENTS and who graduated subsequent
to January first, nineteen hundred ninety-three; or (ii) optometrists
who have been certified for at least five years to use [phase one]
TOPICAL THERAPEUTIC AGENTS and [phase two drugs] THERAPEUTIC PHARMACEU-
TICAL AGENTS FOR TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION in anoth-
er jurisdiction, have demonstrated such use in independently managed
patients, and have been licensed in accordance with section seventy-one
hundred four of this chapter. Provided, however, no optometrist exempt
under this paragraph shall be permitted to use [phase one] TOPICAL ther-
apeutic pharmaceutical agents or [phase two] therapeutic pharmaceutical
agents FOR TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION prior to the
general authorization provided to optometrists licensed in this state.
§ 3. The opening paragraph of paragraph (b) and paragraph (c) of
subdivision 10 of section 7101-a of the education law, as amended by
chapter 506 of the laws of 2021, are amended to read as follows:
Those optometrists having been certified for topical therapeutic phar-
maceutical agents shall be authorized to use and prescribe all topical
therapeutic pharmaceutical agents [specified in paragraph (e) of subdi-
vision one of this section], which are FDA approved and commercially
available for topical use.
(c) Those optometrists having been certified for therapeutic pharma-
ceutical agents for treatment of glaucoma and ocular hypertension shall
be authorized to use and prescribe therapeutic pharmaceutical agents for
treatment of glaucoma and ocular hypertension [specified in paragraph
(f) of subdivision one of this section], which are FDA approved and
commercially available.
§ 4. This act shall take effect immediately.